Giulio Marchesini

53.7k total citations · 16 hit papers
452 papers, 35.3k citations indexed

About

Giulio Marchesini is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Hepatology. According to data from OpenAlex, Giulio Marchesini has authored 452 papers receiving a total of 35.3k indexed citations (citations by other indexed papers that have themselves been cited), including 242 papers in Epidemiology, 134 papers in Endocrinology, Diabetes and Metabolism and 128 papers in Hepatology. Recurrent topics in Giulio Marchesini's work include Liver Disease Diagnosis and Treatment (222 papers), Liver Disease and Transplantation (105 papers) and Diet, Metabolism, and Disease (63 papers). Giulio Marchesini is often cited by papers focused on Liver Disease Diagnosis and Treatment (222 papers), Liver Disease and Transplantation (105 papers) and Diet, Metabolism, and Disease (63 papers). Giulio Marchesini collaborates with scholars based in Italy, United States and United Kingdom. Giulio Marchesini's co-authors include Elisabetta Bugianesi, Giampaolo Bianchi, Gabriele Forlani, Arthur J. McCullough, Ester Vanni, Nazario Melchionda, Riccardo Dalle Grave, Marco Zoli, Marco Lenzi and Stefania Natale and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and PLoS ONE.

In The Last Decade

Giulio Marchesini

443 papers receiving 34.3k citations

Hit Papers

The NAFLD fibrosis score 1999 2026 2008 2017 2007 2003 2001 1999 2002 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The NAFLD fibrosis score
    2007 2.3k citations Giulio Marchesini, Alastair D. Burt et al. Hepatology profile →
  2. Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
    2003 2.1k citations Giulio Marchesini, Elisabetta Bugianesi et al. Hepatology profile →
  3. Nonalcoholic Fatty Liver Disease
    2001 2.1k citations Giulio Marchesini, Giampaolo Bianchi et al. profile →
  4. Association of nonalcoholic fatty liver disease with insulin resistance
    1999 1.3k citations Giulio Marchesini, Giampaolo Bianchi et al. profile →
  5. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma
    2002 1.1k citations Elisabetta Bugianesi, Ester Vanni et al. profile →
  6. Prevalence of and Risk Factors for Nonalcoholic Fatty Liver Disease: The Dionysos Nutrition and Liver Study * #
    2005 997 citations Giorgio Bedogni, L. Miglioli et al. Hepatology profile →
  7. A position statement on NAFLD/NASH based on the EASL 2009 special conference
    2010 828 citations Vlad Ratziu, Stefano Bellentani et al. profile →
  8. Insulin Resistance: A Metabolic Pathway to Chronic Liver Disease *
    2005 688 citations Elisabetta Bugianesi, Giulio Marchesini et al. Hepatology profile →
  9. A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease
    2005 544 citations Elisabetta Bugianesi, Rita Manini et al. profile →
  10. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes
    2008 530 citations Anna Ludovica Fracanzani, Luca Valenti et al. Hepatology profile →
  11. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome
    2014 528 citations Giulio Marchesini et al. Digestive and Liver Disease profile →
  12. Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes
    2001 522 citations Giulio Marchesini et al. profile →
  13. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease†
    2005 507 citations Nicola Villanova, Elisabetta Bugianesi et al. Hepatology profile →
  14. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation
    2018 300 citations Giulio Marchesini et al. profile →
  15. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation
    2019 240 citations Elisabetta Bugianesi, Giulio Marchesini et al. Hepatology profile →
  16. Non-alcoholic fatty liver disease: A patient guideline
    2021 162 citations Giulio Marchesini et al. profile →

Peers

Giulio Marchesini
Comparison fields: 5 of 189
  • Epidemiology 24.7k
  • Endocrinology, Diabetes and Metabolism 12.4k
  • Hepatology 10.8k
  • Physiology 6.0k
  • Surgery 5.4k
Replace Jeanne M. Clark with:
Jeanne M. Clark United States
Christopher D. Byrne United Kingdom
Hannele Yki‐Järvinen Finland
Zobair M. Younossi United States
Enzo Bonora Italy
Michael Roden Germany
Norbert Stefan Germany
James I. Cleeman United States
K. G. M. M. Alberti United Kingdom
Robert W. Schrier United States
Jeanne M. Clark United States View profile →
Citations per field, relative to Giulio Marchesini
Giulio Marchesini · 1×
Citations per year, relative to Giulio Marchesini
Giulio Marchesini · 1×

Countries citing papers authored by Giulio Marchesini

Since Specialization
Citations

This map shows the geographic impact of Giulio Marchesini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giulio Marchesini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giulio Marchesini more than expected).

Fields of papers citing papers by Giulio Marchesini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giulio Marchesini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giulio Marchesini. The network helps show where Giulio Marchesini may publish in the future.

Co-authorship network of co-authors of Giulio Marchesini

This figure shows the co-authorship network connecting the top 25 collaborators of Giulio Marchesini. A scholar is included among the top collaborators of Giulio Marchesini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giulio Marchesini. Giulio Marchesini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Association between Albumin Alterations and Renal Function in Patients with Type 2 Diabetes Mellitus
2024 ·International Journal of Molecular Sciences ·(unknown), Maurizio Baldassarre, (unknown), Daniele Tedesco, Irene Capelli, (unknown), (unknown), Lucia Brodosi, (unknown), Maria Letizia Petroni, Gaetano La Manna, Giulio Marchesini, Marina Naldi, Manuela Bartolini
2
2
Long‐term follow‐up of web‐based and group‐based behavioural intervention in NAFLD in a real world clinical setting
2023 ·Alimentary Pharmacology & Therapeutics ·Maria Letizia Petroni, Santo Colosimo, Lucia Brodosi, Angelo Armandi, Flavio Bertini, Danilo Montesi, Elisabetta Bugianesi, Giulio Marchesini
4
3
Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent
2022 ·Nutrition Metabolism and Cardiovascular Diseases ·Santo Colosimo, Garry D. Tan, Maria Letizia Petroni, Giulio Marchesini, Jeremy Tomlinson
17
4
Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis
2021 ·Liver International ·Santo Colosimo, Federico Ravaioli, Maria Letizia Petroni, Lucia Brodosi, (unknown), (unknown), Anna Simona Sasdelli, Giulio Marchesini, Loris Pironi
33
5
Initial treatment of diabetes in Italy. A nationwide population-based study from of the ARNO Diabetes Observatory
2021 ·Nutrition Metabolism and Cardiovascular Diseases ·Enzo Bonora, (unknown), Giulio Marchesini, Roberto Miccoli, Olga Vaccaro, Gian Paolo Fadini, Nello Martini, Elisa Rossi
6
6
Stress Hyperglycemia and Complications Following Traumatic Injuries in Individuals With/Without Diabetes: The Case of Orthopedic Surgery
2020 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Arianna Mazzotti, Maria Letizia Petroni, Giulio Marchesini, Giampaolo Bianchi
2
7
Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes
2019 ·Journal of Clinical Medicine ·(unknown), Roberto Pippi, (unknown), (unknown), (unknown), Livia Buratta, Vittorio Bini, Giulio Marchesini, Pierpaolo De Feo, Carmine G. Fanelli
22
8
Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)
2018 ·Digestive and Liver Disease ·Sara Montagnese, Francesco Paolo Russo, Piero Amodio, Patrizia Burra, Antonio Gasbarrini, C. Loguercio, Giulio Marchesini, Manuela Merli, Francesca Romana Ponziani, Oliviero Riggio, Carmelo Scarpignato
79
9
Predicting Frailty Condition in Elderly Using Multidimensional Socioclinical Databases
2018 ·Proceedings of the IEEE ·Flavio Bertini, (unknown), Danilo Montesi, Giacomo Veronese, Giulio Marchesini, Paolo Pandolfi
33
10
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
2016 ·Alimentary Pharmacology & Therapeutics ·M. Munteanu, Dina Tiniakos, Quentin M. Anstee, Frédéric Charlotte, Giulio Marchesini, Elisabetta Bugianesi, Michael Trauner, (unknown), Cláudia P. Oliveira, Christopher P. Day, Jean‐François Dufour, Stefano Bellentani, Yen Ngo, (unknown), Hugo Perazzo, Olivier Deckmyn, Pierre Bédossa, Vlad Ratziu, Thierry Poynard
69
11
Weight Loss Expectations and Attrition in Treatment-Seeking Obese Women
2015 ·Obesity Facts ·Riccardo Dalle Grave, Simona Calugi, Angelo Compare, Marwan El Ghoch, Maria Letizia Petroni, Franco Tomasi, Gloria Mazzali, Giulio Marchesini
33
12
Visceral Fat and Body Composition Changes in a Female Population After RYGBP: a Two-Year Follow-Up by DXA
2014 ·Obesity Surgery ·Alberto Bazzocchi, Federico Ponti, (unknown), Danila Diano, (unknown), Ugo Albisinni, Giulio Marchesini, Giuseppe Battista
50
13
Generation and Performance of Outcome Indicators in Liver Disease: The Value Based Medicine in Hepatology Study (VBMH)
2013 ·Hepatology ·(unknown), S. Okolicsanyi, (unknown), (unknown), Manuel Gentiluomo, (unknown), Paolo Angelo Cortesi, L Scalone, LG Mantovani, G Cesana, Patrizia Pontisso, Mario U. Mondelli, Giulio Marchesini, Luca Fabris, Vincenzo Mazzaferro, Patrizia Burra, M. Colledan, S. Fagiuoli, L Belli, Mario Strazzabosco
2
14
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease
2010 ·Gut ·Paola Dongiovanni, Luca Valenti, Raffaela Rametta, Ann K. Daly, Valério Nobili, Enrico Mozzi, Julian Leathart, Andrea Pietrobattista, Alastair D. Burt, Marco Maggioni, Anna Ludovica Fracanzani, Enrico Lattuada, Marco Antonio Zappa, Giancarlo Roviaro, Giulio Marchesini, Christopher P. Day, Silvia Fargion
143
15
Dietary habits, body weight and insulin resistance in nonalcoholic fatty liver disease
2007 ·Endocrinología y Nutrición ·Giulio Marchesini, Rebecca Marzocchi
1
16
Prevalence of and Risk Factors for Nonalcoholic Fatty Liver Disease: The Dionysos Nutrition and Liver Study * # breakdown →
2005 ·Hepatology ·Giorgio Bedogni, L. Miglioli, Flora Masutti, Claudio Tiribelli, Giulio Marchesini, Stefano Bellentani
997
17
Update on nutritional supplementation with branched-chain amino acids
2004 ·Current Opinion in Clinical Nutrition & Metabolic Care ·Giampaolo Bianchi, Rebecca Marzocchi, F. Agostini, Giulio Marchesini
33
18
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome breakdown →
2003 ·Hepatology ·Giulio Marchesini, Elisabetta Bugianesi, Gabriele Forlani, (unknown), Marco Lenzi, Rita Manini, Stefania Natale, Ester Vanni, Nicola Villanova, Nazario Melchionda, Mario Rizzetto
2144
19
Agent Orange and its associated dioxin : assessment of a controversy
1988 ·Elsevier eBooks ·Alvin L. Young, Giulio Marchesini
23
20
HASCHISCH UND FAHRVERHALTEN. EINE EXPERIMENTELLE UNTERSUCHUNG.
1972 ·DMW - Deutsche Medizinische Wochenschrift ·P Kielholz, Leonard S. Goldberg, (unknown), D Ladewig, Giulio Marchesini, Rolf Richter
3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeanne M. Clark Breakdown of academic impact, for papers by Christopher D. Byrne Breakdown of academic impact, for papers by Hannele Yki‐Järvinen Breakdown of academic impact, for papers by Zobair M. Younossi Breakdown of academic impact, for papers by Enzo Bonora Breakdown of academic impact, for papers by Michael Roden Breakdown of academic impact, for papers by Norbert Stefan Breakdown of academic impact, for papers by James I. Cleeman Breakdown of academic impact, for papers by K. G. M. M. Alberti Breakdown of academic impact, for papers by Robert W. Schrier
Rankless by CCL
2026